The Experts below are selected from a list of 68685 Experts worldwide ranked by ideXlab platform

Sarah Spiegel - One of the best experts on this subject based on the ideXlab platform.

Lisa C Edsall - One of the best experts on this subject based on the ideXlab platform.

B L Neubauer - One of the best experts on this subject based on the ideXlab platform.

  • Kinetic analysis of LY320236: Competitive Inhibitor of type I and non-Competitive Inhibitor of type II human steroid 5α-reductase
    The Journal of Steroid Biochemistry and Molecular Biology, 2000
    Co-Authors: A M Mcnulty, J E Audia, K G Bemis, R L Goode, V P Rocco, B L Neubauer
    Abstract:

    Abstract Type I and type II steroid 5α-reductases (5α-R) catalyze the conversion of testosterone (T) to dihydrotestosterone (DHT). LY320236 is a benzoquinolinone (BQ) that inhibits 5α-R activity in human scalp skin ( Ki type I =28.7±1.87 nM) and prostatic homogenates ( Ki type II =10.6±4.5 nM). Lineweaver–Burk, Dixon, and non-linear analysis methods were used to evaluate the kinetics of 5α-R inhibition by LY320236. Non-linear modeling of experimental data evaluated V max in the presence or absence of LY320236. Experimental data modeled to the following equation 1 v = In0c+ Km/ S V max Ki I + 1 V max 1+ Km S fixing the In0c value equal to 1.0 or 0 are consistent with non-Competitive or Competitive inhibition, respectively. LY320236 is a Competitive Inhibitor of type I 5α-R ( In0c =0, Ki =3.39±0.38, RMSE = 1.300) and a non-Competitive Inhibitor of type II 5α-R ( In0c =1, Ki =29.7±3.4, RMSE = 0.0592). These data are in agreement with linear transformation of the data using Lineweaver–Burk and Dixon analyses. These enzyme kinetic data support the contention that the BQ LY320236 is a potent dual Inhibitor with differing modes of activity against the two known human 5α-reductase isozymes. LY320236 represents a class of non-steroidal 5α-R Inhibitors with potential therapeutic utility in treating a variety of androgen dependent disorders.

  • Kinetic analysis of LY320236: Competitive Inhibitor of type I and non-Competitive Inhibitor of type II human steroid 5alpha-reductase.
    The Journal of steroid biochemistry and molecular biology, 2000
    Co-Authors: A M Mcnulty, J E Audia, K G Bemis, R L Goode, V P Rocco, B L Neubauer
    Abstract:

    Type I and type II steroid 5alpha-reductases (5alpha-R) catalyze the conversion of testosterone (T) to dihydrotestosterone (DHT). LY320236 is a benzoquinolinone (BQ) that inhibits 5alpha-R activity in human scalp skin (Ki(typeI)=28.7+/-1.87 nM) and prostatic homogenates (Ki(typeII)=10.6+/-4.5 nM). Lineweaver-Burk, Dixon, and non-linear analysis methods were used to evaluate the kinetics of 5alpha-R inhibition by LY320236. Non-linear modeling of experimental data evaluated V(max) in the presence or absence of LY320236. Experimental data modeled to the following equation 1v=+ fixing the In0c value equal to 1.0 or 0 are consistent with non-Competitive or Competitive inhibition, respectively. LY320236 is a Competitive Inhibitor of type I 5alpha-R (In0c=0, Ki=3.39+/-0.38, RMSE = 1.300) and a non-Competitive Inhibitor of type II 5alpha-R (In0c=1, Ki=29. 7+/-3.4, RMSE = 0.0592). These data are in agreement with linear transformation of the data using Lineweaver-Burk and Dixon analyses. These enzyme kinetic data support the contention that the BQ LY320236 is a potent dual Inhibitor with differing modes of activity against the two known human 5alpha-reductase isozymes. LY320236 represents a class of non-steroidal 5alpha-R Inhibitors with potential therapeutic utility in treating a variety of androgen dependent disorders.

And Burkhard Kleuser - One of the best experts on this subject based on the ideXlab platform.

Olivier Cuvillier - One of the best experts on this subject based on the ideXlab platform.